Breaking: MassBio Applauds House for Passage of PDUFA
Yesterday the House of Representatives approved the bipartisan Food and Drug Administration Reform Act, which included reauthorization of the Prescription Drug User Fee Act (PDUFA).
“We are now another step closer to the reauthorization of PDUFA, which is crucial to guarantee that Massachusetts’ most innovative companies can continue to develop treatments and cures knowing those products face a rigorous and transparent review process,” said MassBio President & CEO Robert K. Coughlin.
Last week the Senate approved the Food and Drug Administration Safety and Innovation Act (FDASIA), which included reauthorization of the Prescription Drug User Fee Act (PDUFA). Now the House and Senate will work to combine their versions into a final bill.
MassBio and the Biotechnology Industry Organization (BIO) have been advocating for passage of PDUFA. We will keep you updated as the Senate and House work to reconcile the two bills.